PAR 5.88% 24.0¢ paradigm biopharmaceuticals limited..

Ann: Paradigm Appoints Experienced US-Based CEO, page-75

  1. 9,820 Posts.
    lightbulb Created with Sketch. 1249
    TanamiRod, we've had limited (read zero) transparency on how Amos has ran the recruitment process and we certainly do not know who was weeded out or declined to continue during the process. My connections made suggestions that they look to go outside the traditional vetting process (LinkedIn references) to ensure they get a complete gauge of his personality strengths and weaknesses to ensure no surprises. Whether they did this I don't know. The only insight into the thinking we've been given was from Paul who effectively wanted there to be an alignment of "values". re they did this I don't know. However, what I do know is that anyone coming off contract may struggle to get a better (read bigger upside) senior appointment in the sector at present. This is not necessary my own bias rather the potential TAM of Zilosul.

    Beaza79 your correct in that you can't assume, however, risk is simply making probabilistic bets on the unknown. In this case we have extensive number of peer reviewed clinical studies on both humans and animals, 2B results & +50 years in veterinary science to suggest the DM qualities of iPPS. Something preserve would now have to happen for this empirical evidence on DM properties to suddenly backflip against us. The most likely outcome is 008 will deliver as hoped and expected.

    BTW you'd both make a good WWF tag team


 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
(20min delay)
Last
24.0¢
Change
-0.015(5.88%)
Mkt cap ! $84.05M
Open High Low Value Volume
25.5¢ 26.5¢ 24.0¢ $167.2K 671.5K

Buyers (Bids)

No. Vol. Price($)
3 108741 24.0¢
 

Sellers (Offers)

Price($) Vol. No.
25.5¢ 9700 2
View Market Depth
Last trade - 16.10pm 13/09/2024 (20 minute delay) ?
PAR (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.